How to Develop a Patient-centered Approach to Afrezza Therapy

Introduction to Patient-Centered Afrezza Therapy

Developing a patient-centered approach to Afrezza therapy represents a fundamental shift in diabetes management that prioritizes individual needs, preferences, and circumstances. Afrezza, an innovative inhaled insulin approved by the FDA, offers a unique alternative to traditional injectable insulins for adults with type 1 and type 2 diabetes. However, the success of this therapy extends far beyond simply prescribing the medication—it requires a comprehensive, personalized care strategy that places the patient at the center of all clinical decisions.

Patient-centered care in the context of Afrezza therapy means recognizing that each individual brings their own set of challenges, goals, lifestyle factors, and concerns to their diabetes management journey. This approach acknowledges that what works for one patient may not work for another, and that optimal outcomes are achieved when healthcare providers actively collaborate with patients rather than simply directing their care. By embracing this philosophy, clinicians can help patients achieve better glycemic control, improved quality of life, and greater satisfaction with their treatment regimen.

The unique delivery mechanism of Afrezza—rapid-acting insulin delivered through inhalation rather than injection—presents both opportunities and challenges that make patient-centered care particularly important. While many patients appreciate the needle-free administration, others may have concerns about inhalation technique, lung function monitoring, or the novelty of the delivery system. Understanding and addressing these individual perspectives is essential for successful therapy implementation and long-term adherence.

Understanding the Fundamentals of Afrezza Insulin

Before developing a patient-centered approach, healthcare providers must have a thorough understanding of Afrezza’s pharmacological properties and clinical applications. Afrezza is a rapid-acting inhaled insulin that uses Technosphere technology to deliver insulin powder to the deep lung, where it is rapidly absorbed into the bloodstream. This unique delivery system results in a faster onset of action compared to subcutaneous rapid-acting insulin analogs, with peak insulin levels occurring within approximately 12-15 minutes after inhalation.

The pharmacokinetic profile of Afrezza more closely mimics the physiological insulin response seen in individuals without diabetes. The rapid absorption and relatively short duration of action—typically 2-3 hours—make it particularly well-suited for controlling postprandial glucose excursions. This characteristic distinguishes Afrezza from injectable rapid-acting insulins, which have a longer duration of action and may contribute to late postprandial or between-meal hypoglycemia if not carefully managed.

Afrezza is available in single-use cartridges containing 4, 8, or 12 units of insulin, which are administered using a small, portable inhaler device. The dosing is based on the patient’s mealtime insulin requirements, and patients may need to use multiple cartridges to achieve their prescribed dose. Understanding these practical aspects of the medication is crucial for helping patients integrate Afrezza into their daily routines effectively.

Comprehensive Patient Assessment and Needs Analysis

The foundation of patient-centered Afrezza therapy begins with a thorough and holistic assessment of each individual patient. This assessment should extend beyond traditional clinical parameters to encompass the full spectrum of factors that influence diabetes management and treatment success. A comprehensive evaluation provides the insights necessary to tailor therapy to each patient’s unique circumstances and maximize the likelihood of positive outcomes.

Medical History and Clinical Evaluation

Begin by conducting a detailed review of the patient’s diabetes history, including type of diabetes, duration of disease, previous treatments, and current glycemic control. Assess their HbA1c levels, frequency and severity of hypoglycemic episodes, and patterns of blood glucose variability throughout the day. Understanding their current insulin regimen—whether they use multiple daily injections, insulin pump therapy, or other medications—provides context for how Afrezza might fit into or modify their existing treatment plan.

Pulmonary function is a critical consideration for Afrezza therapy, as the medication is contraindicated in patients with chronic lung disease such as asthma or chronic obstructive pulmonary disease (COPD). Baseline spirometry testing is required before initiating Afrezza, and periodic monitoring of lung function is necessary during treatment. Document any history of respiratory conditions, smoking status (current, former, or never), and respiratory symptoms that might affect the patient’s ability to use inhaled insulin safely and effectively.

Evaluate comorbid conditions that may impact diabetes management or Afrezza therapy, including cardiovascular disease, kidney disease, neuropathy, retinopathy, and gastroparesis. These conditions may influence treatment goals, monitoring strategies, and the overall approach to diabetes care. Additionally, assess for any medications that might interact with insulin therapy or affect glucose metabolism.

Lifestyle and Daily Routine Assessment

Understanding a patient’s daily life is essential for developing a practical and sustainable treatment plan. Explore their typical daily schedule, including work hours, shift patterns, meal timing, and sleep habits. Patients with irregular schedules, such as shift workers or those who travel frequently, may face unique challenges in maintaining consistent diabetes management routines. The rapid-acting nature of Afrezza can offer flexibility for patients with variable meal times, but this requires careful planning and education.

Assess dietary patterns, including meal frequency, portion sizes, carbohydrate intake, and eating preferences. Understanding whether patients eat regular meals, skip meals, snack frequently, or follow specific dietary patterns (such as low-carbohydrate, Mediterranean, or plant-based diets) helps inform dosing strategies and timing recommendations. The rapid onset of Afrezza makes it particularly important to coordinate dosing with actual food consumption to prevent hypoglycemia.

Physical activity levels and exercise patterns significantly impact insulin requirements and glucose control. Document the type, frequency, intensity, and timing of physical activity, as well as how exercise currently affects the patient’s blood glucose levels. Some patients may benefit from Afrezza’s shorter duration of action, which may reduce the risk of exercise-induced hypoglycemia compared to longer-acting mealtime insulins.

Psychosocial and Behavioral Factors

Diabetes management is deeply influenced by psychological, social, and behavioral factors that must be addressed in patient-centered care. Assess the patient’s emotional well-being, including any history of depression, anxiety, or diabetes distress. These conditions are common among people with diabetes and can significantly impact self-care behaviors, treatment adherence, and overall outcomes. Patients experiencing diabetes burnout or injection fatigue may be particularly interested in alternative delivery methods like Afrezza.

Evaluate health literacy and numeracy skills, as these affect a patient’s ability to understand diabetes education, interpret blood glucose readings, calculate insulin doses, and make appropriate treatment decisions. Tailor educational materials and communication strategies to match each patient’s comprehension level, using plain language, visual aids, and teach-back methods to ensure understanding.

Explore the patient’s support system, including family members, friends, or caregivers who may be involved in their diabetes care. Strong social support can enhance adherence and outcomes, while lack of support may present barriers that need to be addressed. Understanding cultural beliefs, values, and practices related to health and illness helps ensure that treatment recommendations are culturally sensitive and acceptable to the patient.

Assess practical barriers to diabetes management, such as financial constraints, insurance coverage, access to healthcare services, transportation challenges, and competing life priorities. The cost of Afrezza and the requirement for baseline and periodic pulmonary function testing may present financial barriers for some patients. Identifying these obstacles early allows for proactive problem-solving and connection to resources such as patient assistance programs or alternative treatment options when necessary.

Patient Preferences and Treatment Goals

Central to patient-centered care is understanding what matters most to each individual patient. Engage in shared goal-setting conversations that explore the patient’s priorities, concerns, and expectations for diabetes treatment. Some patients may prioritize avoiding hypoglycemia, while others focus on achieving specific HbA1c targets, reducing injection burden, or minimizing treatment interference with daily activities.

Discuss the patient’s previous experiences with insulin therapy, including what has worked well and what challenges they have encountered. Patients who have struggled with injection anxiety, needle phobia, or injection site issues may be particularly motivated to try inhaled insulin. Conversely, patients who are comfortable with injections and concerned about trying a new delivery method may need additional education and support to feel confident about transitioning to Afrezza.

Explore attitudes toward technology and willingness to engage with diabetes management tools such as continuous glucose monitors, insulin pumps, or smartphone apps. While Afrezza itself is a relatively simple device, integrating it with other diabetes technologies can enhance outcomes and patient engagement. Understanding the patient’s comfort level with technology helps guide recommendations for complementary tools and monitoring strategies.

Comprehensive Patient Education Strategies

Education is the cornerstone of patient-centered Afrezza therapy, empowering patients with the knowledge and skills necessary to use the medication safely and effectively. A well-designed education program should be comprehensive yet accessible, delivered in multiple formats, and reinforced over time to ensure retention and mastery of essential concepts.

Mechanism of Action and Pharmacokinetics

Help patients understand how Afrezza works in their body using clear, non-technical language. Explain that Afrezza is a rapid-acting insulin delivered as a powder that is inhaled into the lungs, where it is quickly absorbed into the bloodstream. Use analogies that resonate with patients, such as comparing the rapid absorption through the lungs to how quickly oxygen enters the blood when we breathe.

Emphasize the key differences between Afrezza and injectable rapid-acting insulins, particularly the faster onset and shorter duration of action. Help patients understand that Afrezza begins working within minutes of inhalation and that its effects typically last 2-3 hours, which means it is specifically designed to cover meals rather than provide background insulin coverage. This distinction is crucial for patients to understand why Afrezza is used in combination with long-acting basal insulin for most patients with type 1 diabetes.

Provide visual aids such as graphs or diagrams showing the insulin action curves of Afrezza compared to other insulins. These visual representations can help patients grasp abstract concepts about insulin pharmacokinetics and understand why timing of doses relative to meals is so important with Afrezza therapy.

Proper Inhaler Technique and Device Training

Mastering proper inhaler technique is essential for ensuring consistent insulin delivery and optimal therapeutic outcomes. Provide hands-on training with the Afrezza inhaler, demonstrating each step of the process and then observing the patient perform the technique themselves. Use the teach-back method, asking patients to explain and demonstrate the process to confirm their understanding.

Break down the inhalation process into clear, sequential steps: loading the cartridge into the inhaler, holding the inhaler level with the purple mouthpiece pointing up, tilting the head back slightly, exhaling fully away from the inhaler, placing the mouthpiece in the mouth and closing lips around it, inhaling deeply through the mouth while keeping the inhaler level, holding the breath for as long as comfortable, and then exhaling slowly away from the inhaler. Each step should be practiced until the patient demonstrates proficiency.

Address common technique errors that can reduce insulin delivery, such as not inhaling deeply enough, exhaling into the inhaler, tilting the inhaler at an angle, or not holding the breath after inhalation. Provide tips for success, such as practicing the inhalation technique without medication first, using a mirror to check positioning, or having a family member observe and provide feedback.

Discuss practical aspects of device care and maintenance, including keeping the inhaler clean and dry, storing cartridges properly, and knowing when to replace the inhaler device. Provide written instructions and video resources that patients can reference at home when questions arise.

Dosing Principles and Meal Coverage

Education about Afrezza dosing requires careful attention to help patients understand the unique aspects of this medication. Explain that Afrezza doses are prescribed based on the patient’s mealtime insulin requirements and that the available cartridge strengths (4, 8, and 12 units) may require using multiple cartridges to achieve the prescribed dose. Provide clear examples of how to combine cartridges to reach different dose levels.

Emphasize the importance of timing Afrezza administration at the beginning of meals, ideally within 5 minutes before eating. This timing is critical because of Afrezza’s rapid onset of action—taking it too early can lead to hypoglycemia if the meal is delayed, while taking it too late may result in postprandial hyperglycemia. Help patients develop strategies for remembering to take their dose at the right time, such as keeping the inhaler at the table or setting phone reminders.

Teach patients how to adjust doses based on meal size and carbohydrate content, if appropriate for their treatment plan. Some patients may use carbohydrate counting to determine their Afrezza dose, while others may use a fixed-dose approach. Provide practical examples and practice scenarios to build confidence in dose decision-making.

Discuss what to do in special situations, such as when meals are skipped, delayed, or larger than usual. Patients should understand that if they skip a meal, they should also skip the corresponding Afrezza dose to avoid hypoglycemia. For unexpectedly large meals or high blood glucose levels, provide guidance on when and how to take additional correction doses, if this is part of their treatment plan.

Recognizing and Managing Side Effects

Prepare patients for potential side effects of Afrezza therapy so they know what to expect and when to seek help. The most common side effects include cough, throat pain or irritation, and hypoglycemia. Explain that cough occurs in a significant proportion of patients, typically appears soon after inhalation, and is usually mild and transient. Help patients distinguish between the expected mild cough and more concerning respiratory symptoms that should be reported to their healthcare provider.

Provide comprehensive hypoglycemia education, including recognition of symptoms (shakiness, sweating, confusion, rapid heartbeat, dizziness, hunger), causes (too much insulin, insufficient food, increased physical activity, alcohol consumption), and treatment (the rule of 15: consume 15 grams of fast-acting carbohydrate, wait 15 minutes, recheck blood glucose, and repeat if still low). Ensure patients have glucose tablets or other fast-acting carbohydrate sources readily available and that family members or close contacts know how to recognize and respond to severe hypoglycemia.

Discuss the importance of pulmonary function monitoring, explaining that patients will need spirometry testing at baseline, after the first six months of therapy, and annually thereafter. Help patients understand that this monitoring is a safety measure to detect any changes in lung function early, and that they should report any new or worsening respiratory symptoms such as shortness of breath, wheezing, or persistent cough between scheduled tests.

Address concerns about weight gain, which can occur with any insulin therapy. Provide guidance on healthy eating patterns, portion control, and physical activity to help patients maintain a healthy weight while achieving good glycemic control.

Integration with Blood Glucose Monitoring

Effective use of Afrezza requires regular blood glucose monitoring to assess the medication’s effectiveness and guide dosing decisions. Educate patients about when and how often to check their blood glucose levels, typically before meals, 1-2 hours after meals, at bedtime, and whenever they experience symptoms of hypoglycemia or hyperglycemia. The rapid action of Afrezza makes postprandial monitoring particularly valuable for assessing meal coverage adequacy.

For patients using continuous glucose monitoring (CGM) systems, discuss how to interpret CGM data in the context of Afrezza therapy. The rapid rise and fall of insulin levels with Afrezza may result in different glucose patterns compared to injectable insulins, and patients should understand what glucose curves to expect after meals. Teach patients to look for patterns in their data that might indicate the need for dose adjustments, such as consistently high postprandial glucose levels or frequent hypoglycemia.

Encourage patients to maintain a log or use a smartphone app to record their blood glucose readings, Afrezza doses, meals, physical activity, and any relevant notes. This information is invaluable for identifying patterns, troubleshooting problems, and making informed adjustments to the treatment plan during follow-up visits.

Addressing Patient Concerns and Building Confidence

Transitioning to a new therapy, particularly one with a novel delivery method like Afrezza, naturally raises concerns and questions for patients. Addressing these concerns proactively and empathetically is essential for building patient confidence and promoting successful therapy adoption.

Inhalation Comfort and Respiratory Concerns

Many patients express concern about inhaling medication into their lungs, particularly if they have never used an inhaled medication before. Acknowledge these concerns as valid and provide reassurance based on clinical evidence. Explain that Afrezza has been studied extensively in clinical trials and that the Technosphere particles used to deliver the insulin are designed to be absorbed rapidly and cleared from the lungs.

For patients worried about the sensation of inhalation, explain that most people find the process comfortable and that any initial throat irritation or cough typically diminishes over time as they become accustomed to the medication. Offer to have them practice with the inhaler device (without medication) during the office visit so they can experience the physical process before committing to the therapy.

Address specific concerns about lung safety by explaining the contraindications (chronic lung disease, active lung cancer) and the monitoring protocol in place to detect any changes in lung function. Emphasize that patients with healthy lungs who do not smoke are generally good candidates for Afrezza therapy, and that the required pulmonary function testing provides an additional layer of safety monitoring.

Device Handling and Portability

Patients often have practical questions about carrying and using the Afrezza inhaler in daily life. Discuss the compact size and portability of the inhaler, which is small enough to fit in a pocket or purse. Explain proper storage requirements, including keeping cartridges in their sealed blister packs until use and avoiding exposure to extreme temperatures or moisture.

Address concerns about using Afrezza in public or social situations. Some patients may feel self-conscious about using an inhaler at restaurants or social gatherings. Validate these feelings while helping patients develop strategies for discreet use, such as briefly excusing themselves if they prefer privacy or simply explaining to companions that they are taking their diabetes medication. Many patients find that the inhaler is actually more discreet than giving themselves an injection.

Provide guidance on traveling with Afrezza, including how to pack supplies, maintain proper storage conditions, and navigate airport security. Patients should carry a letter from their healthcare provider explaining their need for the medication and supplies, and they should pack extra cartridges in case of travel delays.

Cost and Insurance Coverage

Financial concerns are a significant barrier to diabetes medication adherence for many patients. Be transparent about the potential costs of Afrezza therapy, including the medication itself, the inhaler device, and required pulmonary function testing. Help patients understand their insurance coverage, including copayments, deductibles, and any prior authorization requirements.

Connect patients with resources to reduce out-of-pocket costs, such as manufacturer copay assistance programs, patient assistance programs for uninsured or underinsured individuals, and pharmacy discount programs. Provide contact information and help patients navigate the application process for these programs when needed. If cost remains prohibitive despite these resources, discuss alternative treatment options that may be more affordable while still meeting the patient’s needs.

Setting Realistic Expectations

Help patients develop realistic expectations about what Afrezza therapy can and cannot achieve. While Afrezza offers advantages such as needle-free delivery and rapid action, it is not a cure for diabetes and requires ongoing commitment to monitoring, dosing, and lifestyle management. Discuss typical timelines for seeing improvements in glycemic control and emphasize that optimization may require several weeks or months of dose adjustments and fine-tuning.

Be honest about potential challenges, such as the learning curve associated with mastering inhaler technique, the need for multiple cartridges for higher doses, and the possibility of side effects like cough. Framing these challenges as normal parts of the adjustment process rather than failures helps patients maintain motivation and persistence when difficulties arise.

Emphasize that diabetes management is a partnership between the patient and healthcare team, and that adjustments to the treatment plan are expected and normal. Encourage patients to view Afrezza therapy as one component of a comprehensive diabetes management strategy that also includes nutrition, physical activity, stress management, and regular medical care.

Personalizing the Afrezza Treatment Plan

The hallmark of patient-centered care is the development of individualized treatment plans that reflect each patient’s unique clinical profile, lifestyle, and preferences. Personalization of Afrezza therapy involves careful consideration of multiple factors to optimize both efficacy and tolerability.

Initial Dosing Strategies

Determining the appropriate starting dose of Afrezza requires consideration of the patient’s current insulin regimen, body weight, insulin sensitivity, and carbohydrate intake. For patients transitioning from injectable rapid-acting insulin, a common approach is to convert their current mealtime insulin dose to an equivalent Afrezza dose, though the conversion is not always one-to-one and may require adjustment based on individual response.

For insulin-naive patients with type 2 diabetes who are adding Afrezza to their existing oral medication or basal insulin regimen, starting with a low dose (typically 4 units) at the largest meal of the day and titrating based on postprandial glucose response is a conservative approach that minimizes hypoglycemia risk while allowing assessment of efficacy and tolerability.

Consider the patient’s meal patterns when designing the dosing schedule. Patients who eat three regular meals per day may use Afrezza with each meal, while those who eat smaller, more frequent meals may need a different approach. Some patients may benefit from using Afrezza only at meals with significant carbohydrate content, while using alternative strategies for low-carbohydrate meals or snacks.

Integration with Basal Insulin and Other Medications

For patients with type 1 diabetes or insulin-requiring type 2 diabetes, Afrezza must be used in combination with long-acting basal insulin to provide 24-hour glucose control. Carefully evaluate the patient’s basal insulin regimen to ensure it is optimized before or concurrent with Afrezza initiation. Inadequate basal insulin coverage can lead to hyperglycemia between meals and overnight, while excessive basal insulin increases hypoglycemia risk.

For patients with type 2 diabetes, consider how Afrezza fits with other glucose-lowering medications such as metformin, GLP-1 receptor agonists, SGLT2 inhibitors, or DPP-4 inhibitors. These medications may have complementary mechanisms of action that enhance overall glycemic control while potentially allowing for lower insulin doses. Be mindful of medications that increase hypoglycemia risk when combined with insulin, and adjust monitoring and education accordingly.

Discuss the potential for simplifying the medication regimen when appropriate. Some patients may be able to discontinue other mealtime medications or reduce the number of daily injections by transitioning to Afrezza, which can improve adherence and quality of life. However, any medication changes should be made thoughtfully with careful monitoring to ensure glycemic control is maintained.

Lifestyle Integration and Behavioral Support

Successful Afrezza therapy requires integration with healthy lifestyle behaviors that support optimal diabetes management. Work with patients to develop a nutrition plan that provides consistent carbohydrate intake at meals, emphasizes whole foods and balanced macronutrients, and aligns with their cultural preferences and food access. Consider referral to a registered dietitian for medical nutrition therapy, which has been shown to improve glycemic control and is a covered benefit under most insurance plans.

Encourage regular physical activity tailored to the patient’s abilities, preferences, and health status. Help patients understand how exercise affects their blood glucose levels and insulin requirements, and provide guidance on adjusting Afrezza doses or carbohydrate intake around physical activity. The shorter duration of action of Afrezza may offer advantages for patients who exercise regularly, as there is less residual insulin activity that could contribute to delayed hypoglycemia.

Address behavioral and psychological aspects of diabetes management that may impact Afrezza therapy success. For patients with diabetes distress, consider referral to a mental health professional with expertise in diabetes care. For those struggling with adherence, explore underlying barriers and work collaboratively to develop solutions, such as simplifying the regimen, using reminder systems, or addressing competing priorities.

Incorporate stress management and sleep hygiene into the treatment plan, as both stress and poor sleep can adversely affect glucose control and insulin sensitivity. Provide resources on relaxation techniques, mindfulness practices, and healthy sleep habits, and consider referral to appropriate specialists when needed.

Special Populations and Considerations

Certain patient populations require special consideration when developing Afrezza treatment plans. Older adults may have unique needs related to cognitive function, dexterity, vision, and hypoglycemia awareness. Assess the patient’s ability to use the inhaler device correctly and to recognize and respond to hypoglycemia. Consider involving caregivers in education and monitoring, and potentially setting less stringent glycemic targets to reduce hypoglycemia risk in this vulnerable population.

For patients with kidney disease, insulin requirements may change as renal function declines, and the risk of hypoglycemia increases. More frequent monitoring and dose adjustments may be necessary, and glycemic targets may need to be individualized based on the stage of kidney disease and overall health status.

Pregnant women should not use Afrezza, as it has not been studied in pregnancy and injectable insulin remains the standard of care for diabetes management during pregnancy. Women of childbearing potential who are using Afrezza should be counseled about the importance of pregnancy planning and the need to transition to injectable insulin before conception or as soon as pregnancy is confirmed.

Patients with a history of eating disorders require careful monitoring and support, as insulin manipulation for weight control is a serious concern in this population. Ensure that these patients have access to appropriate mental health support and that the diabetes care team communicates regularly with mental health providers.

Comprehensive Monitoring and Follow-up Protocols

Ongoing monitoring and regular follow-up are essential components of patient-centered Afrezza therapy, allowing for timely identification of issues, assessment of treatment efficacy, and optimization of the therapeutic regimen. A structured approach to monitoring ensures that no important aspects of care are overlooked while remaining flexible enough to address individual patient needs.

Initial Follow-up and Titration Phase

The first few weeks after initiating Afrezza therapy are critical for establishing proper technique, assessing initial response, and making necessary dose adjustments. Schedule a follow-up contact within one to two weeks of starting Afrezza, either by phone, secure messaging, or in-person visit, to assess how the patient is managing with the new therapy. During this contact, review inhaler technique, address any questions or concerns, evaluate blood glucose patterns, and assess for side effects such as cough or hypoglycemia.

Review the patient’s blood glucose logs or CGM data to identify patterns that suggest the need for dose adjustments. Look for consistent postprandial hyperglycemia that might indicate insufficient Afrezza dosing, or frequent hypoglycemia that suggests doses are too high. Consider whether the timing of doses relative to meals is appropriate, and whether basal insulin adjustments are needed to optimize overall control.

Make dose adjustments incrementally, typically changing one variable at a time to clearly assess the impact of each change. For example, adjust the Afrezza dose at breakfast first, allow several days to assess the effect, then adjust lunch and dinner doses as needed. This systematic approach prevents over-correction and helps patients understand the relationship between their doses and glucose responses.

Plan for additional follow-up contacts every one to two weeks during the titration phase until glycemic targets are achieved and the patient feels confident managing the therapy independently. The frequency of follow-up can be adjusted based on the patient’s progress, comfort level, and complexity of their diabetes management.

Ongoing Monitoring Parameters

Once the patient is stable on Afrezza therapy, establish a regular monitoring schedule that includes both patient self-monitoring and periodic clinical assessments. Self-monitoring of blood glucose remains a cornerstone of diabetes management, and patients should be encouraged to check their glucose levels regularly and record the results. For patients using CGM, review the data at each visit, focusing on key metrics such as time in range, time below range, glucose variability, and the ambulatory glucose profile.

HbA1c testing should be performed every three months until glycemic targets are consistently achieved, then every six months for patients meeting goals. The HbA1c provides a measure of average glucose control over the preceding two to three months and is the primary metric for assessing long-term glycemic control. However, it should be interpreted in the context of glucose variability and hypoglycemia frequency, as a normal HbA1c can mask problematic glucose fluctuations.

Pulmonary function testing is required at baseline before starting Afrezza, after six months of therapy, and annually thereafter. Spirometry should measure forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). A decline of 20% or more in FEV1 from baseline warrants consideration of discontinuing Afrezza. Patients should also be asked about respiratory symptoms at each visit, including cough, shortness of breath, wheezing, or chest tightness.

Monitor for hypoglycemia by asking patients about frequency and severity of low blood glucose episodes, including any episodes requiring assistance from others or resulting in loss of consciousness or seizures. Review the circumstances surrounding hypoglycemic events to identify patterns and contributing factors, and adjust the treatment plan accordingly to minimize recurrence.

Assess for diabetes complications through regular screening for retinopathy, nephropathy, neuropathy, and cardiovascular disease according to established guidelines. Monitor blood pressure, lipid levels, and kidney function, and ensure patients receive recommended preventive care such as foot exams, eye exams, and dental care.

Structured Follow-up Visits

Regular follow-up visits provide opportunities for comprehensive assessment, education reinforcement, and collaborative treatment planning. Structure visits to efficiently cover essential topics while allowing time for patient questions and concerns. A typical follow-up visit for a patient on Afrezza therapy might include the following components:

Review of interval history, including any acute illnesses, hospitalizations, or significant life changes
Assessment of current symptoms and diabetes-related complications
Review of blood glucose data and identification of patterns requiring attention
Evaluation of HbA1c and other laboratory results
Assessment of inhaler technique and medication adherence
Review of hypoglycemia frequency and severity
Inquiry about respiratory symptoms and review of pulmonary function testing when due
Discussion of lifestyle factors including nutrition, physical activity, and stress management
Assessment of psychosocial well-being and diabetes distress
Collaborative goal-setting and treatment plan adjustments
Education on new topics or reinforcement of previous teaching
Coordination with other members of the healthcare team
Scheduling of next appointment and any needed testing

Document all aspects of the visit thoroughly, including specific glucose patterns discussed, dose adjustments made, education provided, and the plan for follow-up. This documentation ensures continuity of care and provides a reference for future visits.

Remote Monitoring and Telehealth

Technology enables more frequent and convenient monitoring and support between in-person visits. Consider implementing remote monitoring strategies such as having patients upload their blood glucose meter or CGM data electronically, using secure messaging for questions and dose adjustments, or conducting video visits for follow-up appointments. These approaches can improve access to care, particularly for patients with transportation barriers, busy schedules, or who live in rural areas.

Establish clear protocols for remote communication, including response timeframes, appropriate uses of different communication channels, and when in-person evaluation is necessary. Ensure that patients understand how to reach the care team with urgent concerns and what constitutes a diabetes emergency requiring immediate medical attention.

Remote monitoring can be particularly valuable during the initial titration phase of Afrezza therapy, allowing for more frequent dose adjustments without requiring multiple office visits. It also facilitates ongoing support and troubleshooting, helping patients feel connected to their care team and more confident in managing their therapy.

Troubleshooting Common Challenges

Even with careful planning and education, patients may encounter challenges with Afrezza therapy that require problem-solving and support from their healthcare team. Anticipating common issues and having strategies ready to address them enhances patient success and satisfaction.

Inadequate Glycemic Control

When patients are not achieving glycemic targets despite Afrezza therapy, systematic evaluation is needed to identify the underlying cause. Review blood glucose patterns to determine whether the problem is fasting hyperglycemia (suggesting inadequate basal insulin), postprandial hyperglycemia (suggesting insufficient Afrezza dosing or timing issues), or both. Assess medication adherence, asking specifically about missed doses, incorrect timing, or improper inhaler technique.

Evaluate lifestyle factors that may be contributing to hyperglycemia, such as excessive carbohydrate intake, large portion sizes, frequent snacking, sedentary behavior, or high stress levels. Work with the patient to identify realistic modifications that can improve glucose control without being overly burdensome.

Consider whether the Afrezza dose is adequate for the patient’s needs. Some patients may require higher doses than initially prescribed, particularly those with significant insulin resistance. Titrate doses upward gradually while monitoring for hypoglycemia, and ensure that patients understand how to use multiple cartridges to achieve higher doses when needed.

Assess whether the timing of Afrezza administration relative to meals is optimal. Taking Afrezza too early before eating can lead to hypoglycemia followed by rebound hyperglycemia, while taking it too late results in postprandial glucose excursions. Help patients develop strategies to ensure consistent timing, such as preparing the inhaler while setting the table or keeping it in a visible location as a reminder.

Persistent Cough or Respiratory Symptoms

Cough is the most common side effect of Afrezza, occurring in approximately 25-30% of patients in clinical trials. For most patients, the cough is mild, occurs shortly after inhalation, and diminishes over time. However, persistent or bothersome cough can affect quality of life and adherence. When patients report problematic cough, first assess the severity, frequency, and impact on daily activities. Determine whether the cough is occurring only after Afrezza use or at other times as well, which helps distinguish Afrezza-related cough from other respiratory conditions.

Review inhaler technique to ensure the patient is using the device correctly, as improper technique can increase throat irritation. Suggest strategies that may reduce cough, such as taking a sip of water before inhalation to moisten the throat, or exhaling more completely before inhaling to allow for a deeper, smoother inhalation.

If cough persists despite these measures and is significantly affecting the patient’s quality of life or willingness to use Afrezza, discuss the option of continuing therapy to see if tolerance develops, or consider transitioning to an alternative insulin regimen. Some patients find that the benefits of needle-free insulin delivery outweigh the inconvenience of mild cough, while others prefer to return to injectable insulin.

For any new or worsening respiratory symptoms beyond mild cough—such as shortness of breath, wheezing, chest tightness, or productive cough—conduct a thorough evaluation to rule out respiratory infection, bronchospasm, or other pulmonary conditions. Perform or arrange for pulmonary function testing if not recently completed, and consider discontinuing Afrezza if there is evidence of declining lung function or significant respiratory compromise.

Recurrent Hypoglycemia

Hypoglycemia is a significant concern with any insulin therapy and requires prompt attention to prevent serious consequences. When patients experience recurrent hypoglycemia, carefully review the circumstances of each episode, including timing relative to meals and Afrezza doses, recent physical activity, alcohol consumption, and any changes in eating patterns or other medications.

Assess whether hypoglycemia is occurring at specific times of day, which can provide clues about the cause. Hypoglycemia occurring 1-2 hours after meals suggests excessive Afrezza dosing for the amount of carbohydrate consumed. Fasting or pre-meal hypoglycemia typically indicates excessive basal insulin rather than a problem with Afrezza. Nocturnal hypoglycemia may be related to evening Afrezza doses, basal insulin, or evening exercise.

Review the patient’s understanding of hypoglycemia treatment and ensure they are using appropriate amounts of fast-acting carbohydrate (15 grams) rather than over-treating, which can lead to rebound hyperglycemia and a cycle of glucose fluctuations. Verify that patients are waiting to see if their glucose rises before consuming additional carbohydrate, and that they are not taking their next Afrezza dose if their glucose is still low or recovering from hypoglycemia.

Make appropriate dose adjustments based on the pattern of hypoglycemia identified. This may involve reducing Afrezza doses at specific meals, adjusting basal insulin, or modifying the timing of doses relative to meals or physical activity. Consider whether the patient would benefit from using a CGM if not already doing so, as real-time glucose information and alerts can help prevent hypoglycemia by allowing for early intervention when glucose is trending low.

Adherence Challenges

Non-adherence to Afrezza therapy can occur for many reasons, including forgetfulness, complexity of the regimen, side effects, cost, lack of perceived benefit, or psychosocial factors. Approach adherence discussions with curiosity and empathy rather than judgment, using open-ended questions to understand the patient’s perspective and barriers.

For patients who forget doses, work together to develop reminder strategies such as smartphone alarms, pill boxes adapted for cartridge storage, visual cues in the environment, or linking Afrezza use to established routines. Simplifying the regimen when possible—such as using fixed doses rather than variable dosing based on carbohydrate counting—may improve adherence for some patients.

If side effects are affecting adherence, address them as described above. If cost is a barrier, revisit assistance programs and resources. If the patient does not perceive benefit from the therapy, review their glucose data together to highlight improvements, or discuss whether expectations need to be recalibrated.

For patients experiencing diabetes burnout or emotional barriers to adherence, provide empathetic support and consider referral to a mental health professional, diabetes educator, or support group. Sometimes acknowledging the difficulty of living with diabetes and validating the patient’s feelings can be therapeutic in itself and open the door to problem-solving conversations.

Empowering Patients Through Shared Decision-Making

True patient-centered care requires moving beyond the traditional paternalistic model of healthcare to embrace shared decision-making, where patients and providers work as partners to make treatment decisions that align with the patient’s values, preferences, and life circumstances. This collaborative approach is particularly important in diabetes care, where patients make dozens of self-management decisions every day.

Principles of Shared Decision-Making

Shared decision-making involves several key elements: ensuring the patient understands their condition and treatment options, exploring the patient’s values and preferences, discussing the benefits and risks of different approaches, and arriving at a decision together that reflects the patient’s informed preferences. This process requires effective communication, mutual respect, and recognition that the patient is the expert on their own life and priorities.

When discussing Afrezza therapy, present it as one option among several for mealtime insulin delivery, explaining the unique features, advantages, and disadvantages compared to alternatives such as injectable rapid-acting insulin analogs or insulin pump therapy. Use decision aids when available to help patients understand and compare their options in a structured way.

Elicit the patient’s values and preferences by asking questions such as: What matters most to you in your diabetes treatment? What concerns you most about your current therapy? What would make diabetes management easier for you? How do you feel about injections versus inhalation? What are your goals for your diabetes control? These conversations provide insight into what will make a treatment plan acceptable and sustainable for each individual patient.

Supporting Patient Autonomy and Self-Management

Empowerment in diabetes care means equipping patients with the knowledge, skills, and confidence to make informed decisions about their daily diabetes management. This includes not only the technical skills of using Afrezza and monitoring glucose, but also the problem-solving skills to adjust their regimen in response to changing circumstances.

Teach patients to recognize patterns in their glucose data and understand what adjustments might be helpful, even if they need to consult with their healthcare provider before making changes. For example, a patient who notices consistently high glucose levels after breakfast might recognize that they need a higher Afrezza dose at that meal. While they should discuss this with their provider, recognizing the pattern themselves demonstrates engagement and self-management capability.

Encourage patients to experiment (safely) with their diabetes management to learn what works best for them. This might include trying different meal timing, exploring how various foods affect their glucose levels, or adjusting their physical activity routine. Provide guidance on how to make these experiments safely, such as checking glucose more frequently when trying something new and knowing when to seek help.

Support the development of problem-solving skills by working through scenarios together. For example: What would you do if you forgot your Afrezza at home when going out to eat? What if you took your dose but then your meal was delayed? How would you handle a day when you’re sick and not eating normally? Practicing these scenarios builds confidence and prepares patients to handle real-life challenges independently.

Building a Supportive Healthcare Team

Patient-centered Afrezza therapy is best delivered through a collaborative team approach that brings together diverse expertise to address the multifaceted needs of people with diabetes. The core team typically includes the primary care provider or endocrinologist, diabetes educator, and pharmacist, with additional team members such as dietitians, mental health professionals, and social workers involved as needed.

Ensure clear communication among team members so that everyone is aware of the treatment plan, recent changes, and any concerns that have been identified. Regular team meetings or case conferences can facilitate coordination and ensure that care is truly integrated rather than fragmented. Electronic health records with shared access can also enhance communication and coordination.

Clarify roles and responsibilities so that patients know who to contact for different types of questions or concerns. For example, the diabetes educator might be the primary contact for questions about inhaler technique or glucose monitoring, while the prescribing provider handles dose adjustments and manages complications. Having clear pathways for communication reduces patient confusion and ensures timely responses to concerns.

Involve family members or support persons in the care team when appropriate and with the patient’s permission. These individuals can provide valuable support, help with monitoring and problem-solving, and serve as advocates for the patient. However, be mindful of maintaining appropriate boundaries and ensuring that the patient’s autonomy and privacy are respected.

Leveraging Technology and Digital Health Tools

The integration of technology and digital health tools can significantly enhance patient-centered Afrezza therapy by improving monitoring, facilitating communication, supporting self-management, and providing data-driven insights for treatment optimization. While technology should complement rather than replace human interaction and clinical judgment, it offers powerful capabilities that can improve outcomes and patient experience.

Continuous Glucose Monitoring Integration

Continuous glucose monitoring (CGM) systems provide real-time glucose readings and trend information that can be particularly valuable for patients using Afrezza. The rapid onset and short duration of action of Afrezza means that postprandial glucose patterns may differ from those seen with injectable insulins, and CGM allows patients and providers to see these patterns clearly and make informed adjustments.

CGM data can help identify whether Afrezza doses are adequate for meal coverage by showing the postprandial glucose rise and how quickly glucose returns to target range. It can also reveal hypoglycemia that might otherwise go undetected, particularly nocturnal hypoglycemia or asymptomatic hypoglycemia in patients with impaired hypoglycemia awareness.

Teach patients how to interpret their CGM data, focusing on actionable metrics such as time in range (typically 70-180 mg/dL), time below range, glucose variability, and the ambulatory glucose profile. Help them understand that the goal is not perfection but rather improvement over time, and that CGM data provides valuable information for making adjustments to their therapy.

Many CGM systems allow for data sharing with healthcare providers and family members, which can facilitate remote monitoring and support. Consider implementing protocols for reviewing patient CGM data between visits and reaching out proactively when concerning patterns are identified, such as frequent hypoglycemia or persistent hyperglycemia.

Mobile Apps and Digital Diabetes Management Platforms

Smartphone applications and digital platforms offer numerous features that can support Afrezza therapy, including glucose tracking, medication logging, carbohydrate counting, dose calculators, trend analysis, and educational content. Some apps integrate data from multiple sources—glucose meters, CGM systems, fitness trackers, and food logs—to provide a comprehensive view of factors affecting glucose control.

Help patients identify apps that meet their needs and preferences, considering factors such as ease of use, features offered, cost, and compatibility with their devices and other diabetes technology. Provide guidance on how to use these tools effectively without becoming overwhelmed by data or spending excessive time on diabetes management tasks.

Digital platforms that facilitate communication between patients and providers can enhance access to care and support timely problem-solving. Secure messaging, video visits, and remote data review capabilities allow for more frequent touchpoints without requiring in-person visits, which can be particularly valuable during the initial titration phase of Afrezza therapy or when troubleshooting challenges.

Educational Resources and Online Support

Digital educational resources can supplement in-person education and provide patients with information they can access anytime, anywhere. Video demonstrations of proper Afrezza inhaler technique, interactive modules on diabetes self-management topics, and downloadable guides can reinforce learning and serve as references when questions arise at home.

Direct patients to reputable online resources for diabetes education and support, such as the American Diabetes Association (https://www.diabetes.org), JDRF (https://www.jdrf.org), and the manufacturer’s website for Afrezza-specific information. Caution patients about the variable quality of health information online and provide guidance on evaluating the credibility of sources.

Online support communities and social media groups can provide peer support, practical tips, and emotional encouragement for people using Afrezza or managing diabetes more generally. While these communities should not replace professional medical advice, they can be valuable sources of lived experience and social connection. Some patients find it helpful to connect with others who use Afrezza to share experiences and strategies.

Addressing Health Equity and Access Barriers

Patient-centered care must acknowledge and address the social determinants of health and systemic barriers that affect diabetes outcomes and access to therapies like Afrezza. Health equity means that everyone has a fair and just opportunity to achieve their optimal health, regardless of race, ethnicity, socioeconomic status, geographic location, or other social factors. However, significant disparities exist in diabetes prevalence, complications, and access to advanced therapies.

Social determinants of health—the conditions in which people are born, live, work, and age—profoundly influence diabetes management and outcomes. Food insecurity, housing instability, lack of transportation, limited health literacy, and financial constraints can all create barriers to optimal diabetes care. When developing Afrezza treatment plans, consider these factors and work with patients to identify realistic strategies that account for their life circumstances.

For patients experiencing food insecurity, connect them with resources such as food banks, nutrition assistance programs, and community meal programs. Recognize that recommendations to eat regular, balanced meals may not be feasible for someone who lacks consistent access to food, and adjust expectations and treatment plans accordingly.

Transportation barriers can prevent patients from attending appointments, picking up medications, or accessing pulmonary function testing required for Afrezza therapy. Explore options such as telehealth visits, mail-order pharmacy services, or connection to transportation assistance programs to reduce these barriers.

Addressing Financial Barriers

The cost of Afrezza and associated care (inhaler device, cartridges, pulmonary function testing, glucose monitoring supplies) can be prohibitive for many patients, particularly those who are uninsured, underinsured, or have high deductibles. Financial toxicity—the burden of healthcare costs on patients—can lead to medication non-adherence, rationing of supplies, and worsening health outcomes.

Proactively discuss costs with patients and explore all available options for reducing out-of-pocket expenses. This includes manufacturer copay assistance programs, patient assistance programs for low-income individuals, pharmacy discount programs, and generic or biosimilar alternatives when available. Some patients may benefit from working with a social worker or financial counselor to navigate insurance coverage and assistance programs.

Be prepared to adjust treatment plans when cost is prohibitive despite assistance programs. While Afrezza may offer advantages for some patients, it is not the only option for mealtime insulin delivery, and ensuring that patients have access to affordable, effective therapy is more important than prescribing any particular medication. Engage in honest conversations about cost-effectiveness and help patients make informed decisions that balance clinical benefits with financial feasibility.

Cultural Competence and Linguistic Accessibility

Providing culturally competent care means understanding and respecting the diverse cultural backgrounds, beliefs, values, and practices of patients. Cultural factors can influence health behaviors, communication styles, family dynamics, dietary patterns, and attitudes toward illness and treatment. Strive to learn about the cultural backgrounds of the patient populations you serve and adapt your approach accordingly.

Use professional interpreter services for patients with limited English proficiency rather than relying on family members, which can compromise accuracy, confidentiality, and patient autonomy. Provide educational materials in the patient’s preferred language when possible, and ensure that written materials are at an appropriate literacy level.

Be aware of your own cultural assumptions and biases, and how these might affect your interactions with patients and clinical decision-making. Approach each patient as an individual with their own unique perspective, and avoid making assumptions based on cultural stereotypes. Ask open-ended questions to understand each patient’s beliefs, preferences, and concerns rather than assuming you know based on their cultural background.

Quality Improvement and Outcome Measurement

Implementing patient-centered Afrezza therapy at a practice or system level requires attention to quality improvement processes and outcome measurement. Systematic approaches to monitoring and improving care quality ensure that all patients receive evidence-based, patient-centered care and that disparities in care and outcomes are identified and addressed.

Key Performance Indicators

Establish key performance indicators (KPIs) to monitor the quality of Afrezza therapy in your practice. Clinical outcome measures might include the percentage of patients achieving HbA1c targets, frequency of hypoglycemia, time in range for patients using CGM, and rates of diabetes-related complications. Process measures might include completion of baseline and follow-up pulmonary function testing, documentation of inhaler technique assessment, and frequency of follow-up visits during the titration phase.

Patient-reported outcome measures are equally important in patient-centered care. These might include treatment satisfaction, quality of life, diabetes distress, and patient-reported adherence. Consider using validated instruments such as the Diabetes Treatment Satisfaction Questionnaire or the Problem Areas in Diabetes scale to systematically assess these outcomes.

Regularly review these metrics to identify areas for improvement and track progress over time. Share aggregate data with the care team to celebrate successes and engage in collaborative problem-solving when gaps are identified. Use data to drive quality improvement initiatives, such as developing standardized education protocols, implementing reminder systems for pulmonary function testing, or enhancing care coordination processes.

Continuous Learning and Adaptation

Patient-centered care is an evolving practice that requires ongoing learning, reflection, and adaptation. Stay current with emerging evidence about Afrezza therapy, new diabetes technologies, and best practices in patient-centered care through continuing education, professional conferences, and peer-reviewed literature. Participate in professional communities of practice where clinicians share experiences and learn from one another.

Seek feedback from patients about their experiences with Afrezza therapy and your practice’s care delivery. Patient satisfaction surveys, focus groups, or individual conversations can provide valuable insights into what is working well and where improvements are needed. Be open to constructive criticism and willing to make changes based on patient input.

Engage in reflective practice, regularly examining your own clinical decision-making, communication patterns, and assumptions. Consider participating in peer review or case conferences where you can discuss challenging cases and receive feedback from colleagues. This ongoing reflection and learning helps ensure that your practice continues to evolve and improve over time.

Future Directions and Emerging Considerations

The landscape of diabetes care continues to evolve rapidly, with new technologies, medications, and care delivery models emerging regularly. Staying informed about these developments and considering how they might enhance patient-centered Afrezza therapy will help ensure that patients have access to the most effective and innovative care options.

Advances in insulin formulations and delivery systems may offer new options for patients in the future. Research into ultra-rapid-acting insulins, smart insulin pens with dose tracking and reminders, and closed-loop insulin delivery systems continues to progress. Understanding how Afrezza fits within the broader landscape of insulin therapy options helps clinicians guide patients toward the most appropriate choices for their individual needs.

Artificial intelligence and machine learning applications in diabetes care show promise for predicting glucose patterns, recommending dose adjustments, and identifying patients at risk for complications. As these technologies mature and become more widely available, they may enhance the ability to personalize Afrezza therapy and optimize outcomes. However, it will be important to ensure that these tools augment rather than replace the human elements of patient-centered care, such as empathy, shared decision-making, and individualized support.

The growing emphasis on value-based care and patient-centered medical homes creates opportunities to enhance care coordination, team-based care, and patient engagement in diabetes management. These models align well with the principles of patient-centered Afrezza therapy and may provide infrastructure and resources to support comprehensive, coordinated care for people with diabetes.

Ongoing research into the long-term outcomes of Afrezza therapy, optimal patient selection criteria, and strategies for maximizing adherence and effectiveness will continue to inform clinical practice. Participating in or staying informed about clinical research helps ensure that practice remains evidence-based and that patients benefit from the latest scientific advances.

Conclusion: The Path Forward in Patient-Centered Afrezza Therapy

Developing a patient-centered approach to Afrezza therapy represents a commitment to placing the individual patient at the heart of all clinical decisions and care processes. This approach recognizes that successful diabetes management extends far beyond prescribing the right medication—it requires understanding each patient’s unique circumstances, preferences, and goals; providing comprehensive education and support; fostering collaborative relationships; addressing barriers to care; and continuously monitoring and adapting the treatment plan to optimize outcomes.

Afrezza offers a unique option for mealtime insulin delivery that may benefit many patients, particularly those who struggle with injection anxiety, prefer needle-free administration, or need the flexibility of rapid-acting insulin with a short duration of action. However, realizing these benefits requires thoughtful implementation that accounts for individual patient factors, careful attention to education and technique training, systematic monitoring and follow-up, and proactive problem-solving when challenges arise.

The principles of patient-centered care—respect for patient preferences, coordination and integration of care, information and education, physical comfort, emotional support, involvement of family and friends, continuity and transition, and access to care—provide a framework for delivering high-quality Afrezza therapy that enhances both clinical outcomes and patient experience. By embracing these principles and implementing the strategies outlined in this comprehensive guide, healthcare providers can help patients achieve better glycemic control, improved quality of life, and greater satisfaction with their diabetes care.

As the field of diabetes care continues to evolve, maintaining a patient-centered focus will remain essential for ensuring that new therapies and technologies truly serve the needs of the people living with diabetes. By listening to patients, respecting their autonomy, addressing their concerns, and working in partnership to achieve their goals, healthcare providers can make a meaningful difference in the lives of people using Afrezza therapy and contribute to better health outcomes for all people with diabetes.

The journey toward optimal diabetes management is ongoing, requiring persistence, flexibility, and collaboration between patients and their healthcare teams. With a patient-centered approach to Afrezza therapy, this journey can be one of empowerment, hope, and continuous improvement, ultimately leading to healthier, more fulfilling lives for people living with diabetes.

Table of Contents